JPS6117467B2 - - Google Patents

Info

Publication number
JPS6117467B2
JPS6117467B2 JP2246681A JP2246681A JPS6117467B2 JP S6117467 B2 JPS6117467 B2 JP S6117467B2 JP 2246681 A JP2246681 A JP 2246681A JP 2246681 A JP2246681 A JP 2246681A JP S6117467 B2 JPS6117467 B2 JP S6117467B2
Authority
JP
Japan
Prior art keywords
urease
acid
weight
solution
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP2246681A
Other languages
Japanese (ja)
Other versions
JPS57138389A (en
Inventor
Toshiro Kikuchi
Minoru Ando
Yoshitaka Nakagiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP2246681A priority Critical patent/JPS57138389A/en
Publication of JPS57138389A publication Critical patent/JPS57138389A/en
Publication of JPS6117467B2 publication Critical patent/JPS6117467B2/ja
Granted legal-status Critical Current

Links

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は安定なウレアーゼ組成物に関するもの
である。 古くから知られ、又、数多く使用されているウ
レアーゼは現在、臨床検査の分野で益々、その需
要が増すとともに、高度の精製品が必要となつて
来た。しかしながら、高度に精製されたウレアー
ゼは頗る不安定で、種々の安定化の試みが行われ
ている。その試みの一つとして、チオール化合
物、例えばシステイン、メルカプトエタノールな
どを加えること、あるいはEDTA、マレイン酸、
クエン酸塩などを添加することが行なわれてき
た。しかし、これらの化合物をそれぞれ単独で添
加しても満足すべき結果が得られなかつた。また
安定剤としてグルタチオン、EDTA及びクエン酸
塩の混合物を含有する調整物(特開昭52−117488
号公報)などが検討されているが、十分な効果は
発揮されていない。 本発明者らはこのような事情を考慮し、さらに
安定なウレアーゼを得るために種々鋭意研究した
結果、チオール化合物、キレート試薬および二塩
基酸またはその塩の混合物を添加すると、従来の
安定化法に比べて著しく安定化されることを見出
し、本発明に到達した。すなわち本発明はウレア
ーゼ、チオール化合物、キレート試薬および有機
二塩基酸またはその塩の混合物を含有することを
特徴とする安定なウレアーゼ組成物である。 本発明では単独で用いられた個々の安定剤に比
べ、著しく安定化されるばかりでなく、またクエ
ン酸などの三塩基酸などの混合物を用いる方法
(特開昭51−117488号)に比べて、明らかに安定
化効果が優れる。また、得られる酵素粉末の吸湿
性においても三塩基酸を加える方法に比べて、明
らかに優れる。さらに本発明では高価なグルタチ
オンなどの添加量を低く抑え、安定性のよい酵素
粉末が得られるばかりでなく、吸湿性の少ない標
品となり、高純度な酵素製剤が得られる。 本発明におけるウレアーゼとはウレアーゼ溶液
又はウレアーゼ粉末であり、例えば豆類を細砕、
粉砕し、粗酵素液を抽出し、硫安などによる塩
析、有機溶媒などによる溶媒沈澱、イオン交換体
を用いる吸着分画又はゲル過などの方法により
得られた溶液又はその減圧乾燥粉末、凍結乾燥粉
末などがある。 本発明に用いるチオール化合物とは、グルタチ
オン、ジチオスレイトール、ジチオエリスリトー
ル、システイン、メルカプトエタノールなどのチ
オール基を有する還元性物質をいう。特にグルタ
チオン、ジチオスレイトール、ジチオエリスリト
ールが好ましい。 本発明に用いるキレート試薬とは、例えばエチ
レンジアミン四酢酸(EDTA)及びその塩、ニト
リロ三酢酸及びその塩、シクロヘキサンジアミン
四酢酸及びその塩など広く一般に用いられている
化合物をいう。特にEDTA、ニトリロ三酢酸が好
ましい。 本発明に用いる有機二塩基酸及びその塩とはシ
ユウ酸、マロン酸、コハク酸、グルタル酸などの
飽和ジカルボン酸及びその塩、リンゴ酸、酒石
酸、イソ酒石酸などのヒドロキシジカルボン酸及
びその塩、マイレン酸、フマル酸、イタコン酸、
グルタコン酸などの不飽和ジカルボン酸及びその
塩などをいう。特にシユウ酸、リンゴ酸、フマル
酸が好ましい。塩としてはアルカリ金属塩、アル
カリ土類金属塩がある。 本発明ではウレアーゼ1.0重量部に、チオール
化合物0.0001〜0.5重量部、キレート化合物0.01〜
5.0重量部、および有機二塩基酸及びその塩0.01
〜100重量部を添加する。特にチオール化合物は
ウレアーゼ1.0重量部に対し、0.02〜0.05重量部が
好ましく、キレート化合物はウレアーゼ1.0重量
部に対し、0.1〜1.0重量部が好ましく、有機二塩
基酸及びその塩はウレアーゼ1.0重量部に対して
0.2〜50重量部が好ましい。 本発明の安定剤、チオール化合物、キレート化
合物および有機二塩基酸及びその塩に加えて、血
清アルブミン、特に牛血清アルブミン(BSA)
を加えると、ウレアーゼの安定化は一段と向上す
る。血清アルブミンの添加量はウレアーゼ1.0重
量部に対し、0〜10重量部、特に0.5〜5重量部
であることが好ましい。 本発明において、ウレアーゼに安定剤を添加す
る方法は特に制限はないが、例えばウレアーゼ溶
液にEDTAを溶解し、PHを7.5に調整した後、グ
ルタチオンを添加し溶解し、さらに二塩基酸又は
その塩および必要により牛血清アルブミンを添加
し溶解して、再びPHを7.5に調整し、得られた液
を凍結乾燥する方法がある。 次に本発明を実施例により説明する。 なお、ウレアーゼ活性測定法はインドフエノー
ル法を用い、0.1M尿素溶液(PH7.0)に30℃にお
いて5分間酵素を作用させた時、5分間当り1mg
のアンモニア態窒素を遊離する酵素力を1単位と
した。 インドフエノール法とは下記試薬を用い、下記
操作により行う方法である。 試 薬 フエノール試薬溶液:フエノール10.0g、ニト
ロプルシドナトリウム50mg/500ml 次亜塩素酸アルカリ溶液:水酸化ナトリウム5
g、次亜塩素酸ナトリウム2.5ml/500ml 0.1M尿素基質溶液:尿素3.0g/0.01Mリン酸
緩衝液(PH)500ml 酵素希釈溶液:0.01Mリン酸緩衝液(PH7.0)
にウレアーゼ酵素粉末を希釈する。 操 作 尿素基質溶液2mlを試験管にとり、30℃で5分
間置き、温度が一定になつたところで酵素希釈溶
液を0.5ml添加し反応を開始する。30℃で15分間
反応させた後、フエノール試薬溶液1.0ml、次亜
塩素酸アルカリ溶液1.0mlを加える。30℃で30分
間放置後、吸光度530nmにて測定する。対照は酵
素希釈溶液を、次亜塩素酸アルカリ溶液を加えた
のち、添加したものを使用する。 実施例 1 ウレアーゼ400単位/ml(蛋白含量10mg/ml)
にグルタチオン1mM、EDTA10mMおよび第1表
に示される有機酸20mMを添加して、組成物を調
製し、凍結乾燥した後、50℃におけるウレアーゼ
の残存活性を測定した。その結果を第1表に示
す。
The present invention relates to stable urease compositions. Urease, which has been known for a long time and is widely used, is currently in increasing demand in the field of clinical testing and requires highly purified products. However, highly purified urease is extremely unstable, and various attempts have been made to stabilize it. One of the attempts is to add thiol compounds such as cysteine, mercaptoethanol, EDTA, maleic acid, etc.
Additions such as citrate have been used. However, even when each of these compounds was added alone, satisfactory results could not be obtained. Also, a preparation containing a mixture of glutathione, EDTA and citrate as a stabilizer (JP-A-52-117488
(No. 2) are being considered, but they have not been sufficiently effective. Taking these circumstances into consideration, the present inventors conducted various intensive studies to obtain a more stable urease. As a result, the addition of a mixture of a thiol compound, a chelating reagent, and a dibasic acid or its salt could eliminate the conventional stabilization method. The present invention has been achieved based on the discovery that it is significantly more stable than the conventional method. That is, the present invention is a stable urease composition characterized by containing a mixture of urease, a thiol compound, a chelating reagent, and an organic dibasic acid or a salt thereof. The present invention not only achieves remarkable stabilization compared to individual stabilizers used alone, but also compared to the method using a mixture of tribasic acids such as citric acid (Japanese Patent Application Laid-Open No. 117488/1983). , the stabilizing effect is clearly superior. Furthermore, the hygroscopicity of the resulting enzyme powder is clearly superior to the method of adding tribasic acid. Furthermore, according to the present invention, the amount of expensive glutathione and the like added can be kept low, and not only a highly stable enzyme powder can be obtained, but also a standard product with low hygroscopicity and a highly pure enzyme preparation can be obtained. Urease in the present invention refers to urease solution or urease powder, for example, by crushing beans,
Grinding, extracting the crude enzyme solution, salting out with ammonium sulfate, etc., solvent precipitation with organic solvents, etc., adsorption fractionation using an ion exchanger, gel filtration, etc., resulting in a solution, vacuum-dried powder, or freeze-drying. There are powders etc. The thiol compound used in the present invention refers to a reducing substance having a thiol group, such as glutathione, dithiothreitol, dithioerythritol, cysteine, and mercaptoethanol. Particularly preferred are glutathione, dithiothreitol, and dithioerythritol. The chelating reagent used in the present invention refers to compounds that are widely used, such as ethylenediaminetetraacetic acid (EDTA) and its salts, nitrilotriacetic acid and its salts, and cyclohexanediaminetetraacetic acid and its salts. Particularly preferred are EDTA and nitrilotriacetic acid. Organic dibasic acids and their salts used in the present invention include saturated dicarboxylic acids and their salts such as oxalic acid, malonic acid, succinic acid, and glutaric acid, hydroxydicarboxylic acids and their salts such as malic acid, tartaric acid, and isotartaric acid, and mylene. acids, fumaric acid, itaconic acid,
Refers to unsaturated dicarboxylic acids such as glutaconic acid and their salts. Particularly preferred are oxalic acid, malic acid, and fumaric acid. Salts include alkali metal salts and alkaline earth metal salts. In the present invention, 1.0 parts by weight of urease, 0.0001 to 0.5 parts by weight of a thiol compound, and 0.01 to 0.01 parts by weight of a chelate compound.
5.0 parts by weight, and 0.01 organic dibasic acids and their salts
Add ~100 parts by weight. In particular, the thiol compound is preferably 0.02 to 0.05 parts by weight per 1.0 parts by weight of urease, the chelate compound is preferably 0.1 to 1.0 parts by weight per 1.0 parts by weight of urease, and the organic dibasic acid and its salt is preferably added to 1.0 parts by weight of urease. for
0.2 to 50 parts by weight is preferred. In addition to the stabilizers of the invention, thiol compounds, chelating compounds and organic dibasic acids and their salts, serum albumin, especially bovine serum albumin (BSA)
The addition of urease further improves the stabilization of urease. The amount of serum albumin added is preferably 0 to 10 parts by weight, particularly 0.5 to 5 parts by weight, per 1.0 part by weight of urease. In the present invention, there are no particular limitations on the method of adding a stabilizer to urease, but for example, EDTA is dissolved in a urease solution, the pH is adjusted to 7.5, glutathione is added and dissolved, and then a dibasic acid or its salt is added. Alternatively, if necessary, bovine serum albumin is added and dissolved, the pH is adjusted to 7.5 again, and the resulting solution is freeze-dried. Next, the present invention will be explained by examples. The urease activity measurement method uses the indophenol method, and when the enzyme is allowed to act on a 0.1M urea solution (PH7.0) for 5 minutes at 30°C, 1 mg per 5 minutes is measured.
The enzymatic power to liberate ammonia nitrogen was defined as one unit. The indophenol method is a method using the following reagents and performing the following operations. Reagents Phenol reagent solution: phenol 10.0g, sodium nitroprusside 50mg/500ml Alkaline hypochlorite solution: Sodium hydroxide 5
g, Sodium hypochlorite 2.5ml/500ml 0.1M urea substrate solution: urea 3.0g/0.01M phosphate buffer (PH) 500ml Enzyme dilution solution: 0.01M phosphate buffer (PH7.0)
Dilute the urease enzyme powder. Procedure: Place 2 ml of the urea substrate solution in a test tube, leave it at 30°C for 5 minutes, and when the temperature becomes constant, add 0.5 ml of the diluted enzyme solution to start the reaction. After reacting at 30°C for 15 minutes, add 1.0 ml of phenol reagent solution and 1.0 ml of alkaline hypochlorite solution. After standing at 30°C for 30 minutes, absorbance is measured at 530nm. As a control, use a diluted enzyme solution added after adding an alkaline hypochlorite solution. Example 1 Urease 400 units/ml (protein content 10 mg/ml)
A composition was prepared by adding 1mM glutathione, 10mM EDTA, and 20mM of the organic acid shown in Table 1, and after freeze-drying, the residual activity of urease at 50°C was measured. The results are shown in Table 1.

【表】【table】

【表】 実施例 2 実施例1と同様にして、下記のような組成物を
調整し、凍結乾燥した後、50℃におけるウレアー
ゼ活性の残存性を測定した。その結果を第2表に
示す。 ウレアーゼ 400単位/ml(蛋白含量10mg/ml) グルタチオン 1mM EDTA 10mM BSA 5mg/ml 各有機酸 20mM
[Table] Example 2 The following composition was prepared in the same manner as in Example 1, and after freeze-drying, the persistence of urease activity at 50°C was measured. The results are shown in Table 2. Urease 400 units/ml (Protein content 10mg/ml) Glutathione 1mM EDTA 10mM BSA 5mg/ml Each organic acid 20mM

【表】 実施例 3 実施例2にて調整した酵素粉末100mgを温度25
℃、湿度70%の状態における吸湿速度を検討し
た。吸湿速度は経時的な重量の増加により測定し
た。結果は第3表に示した。
[Table] Example 3 100 mg of the enzyme powder prepared in Example 2 was heated to 25
We investigated the moisture absorption rate at ℃ and 70% humidity. Moisture absorption rate was measured by weight increase over time. The results are shown in Table 3.

【表】【table】

Claims (1)

【特許請求の範囲】 1 ウレアーゼ、チオール化合物、キレート試薬
および有機二塩基酸またはその塩を含有すること
を特徴とする安定なウレアーゼ組成物。 2 ウレアーゼ、チオール化合物、キレート試
薬、血清アルブミンおよび有機二塩基酸またはそ
の塩を含有することを特徴とする特許請求の範囲
第1項記載の安定なウレアーゼ組成物。
[Scope of Claims] 1. A stable urease composition comprising urease, a thiol compound, a chelating reagent, and an organic dibasic acid or a salt thereof. 2. The stable urease composition according to claim 1, which contains urease, a thiol compound, a chelating reagent, serum albumin, and an organic dibasic acid or a salt thereof.
JP2246681A 1981-02-17 1981-02-17 Stable urease composition Granted JPS57138389A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2246681A JPS57138389A (en) 1981-02-17 1981-02-17 Stable urease composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2246681A JPS57138389A (en) 1981-02-17 1981-02-17 Stable urease composition

Publications (2)

Publication Number Publication Date
JPS57138389A JPS57138389A (en) 1982-08-26
JPS6117467B2 true JPS6117467B2 (en) 1986-05-07

Family

ID=12083476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2246681A Granted JPS57138389A (en) 1981-02-17 1981-02-17 Stable urease composition

Country Status (1)

Country Link
JP (1) JPS57138389A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0213156A1 (en) * 1985-02-11 1987-03-11 Travenol-Genentech Diagnostics Stabilized enzyme substrate solutions
WO1995000662A1 (en) * 1993-06-21 1995-01-05 Boehringer Mannheim Corporation Diagnostic reagent stabilizer
US8241697B2 (en) 2007-12-20 2012-08-14 Abbott Point Of Care Inc. Formation of immobilized biological layers for sensing
US8268604B2 (en) * 2007-12-20 2012-09-18 Abbott Point Of Care Inc. Compositions for forming immobilized biological layers for sensing

Also Published As

Publication number Publication date
JPS57138389A (en) 1982-08-26

Similar Documents

Publication Publication Date Title
Hammond et al. The mechanism of ficin-catalysed reactions
JP4621326B2 (en) Teprenone stabilized composition
US4409233A (en) Highly concentrated preparations of dopa compounds
CA1203168A (en) Pharmaceutical composition containing a stabilised glycyrrhetinic acid derivative
JPH0335920B2 (en)
US4448882A (en) Stabilized peroxidase compositions
EP0307975A2 (en) Improvements relating to assay reagents
JPS6117467B2 (en)
US4046879A (en) Antiviral compositions
Owren The fifth coagulation factor (Factor V'). Preparation and properties
JPH0257920B2 (en)
JPS5836954B2 (en) Enzyme stabilizer
EP3178927A1 (en) Protein-stabilizing agent and protein-stabilizing method
JPH0154997B2 (en)
CA1136550A (en) Pharmaceutical composition containing thymidine
JPH0446558B2 (en)
JPS6231912B2 (en)
JP4413340B2 (en) Enzyme stabilization method and stabilized measurement reagent
JPS6331446B2 (en)
JPS61236676A (en) Stabilization for liquid fertilizer
Marescau et al. Excretion of α-keto-δ-guanidinovaleric acid and its cyclic form in patients with hyperargininemia
US5183751A (en) Stabilization of peroxidase solutions by para-amino-salicyclic acid
US2611732A (en) Compositions containing mixtures of 4-aminosalicylic acid and its basic calcium salt
JPS6440B2 (en)
JP2712566B2 (en) Vitamin B6 stabilization method